About: Controllable inhibition of hepatitis B virus replication by a DR1-targeting short hairpin RNA (shRNA) expressed from a DOX-inducible lentiviral vector

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Controllable inhibition of hepatitis B virus replication by a DR1-targeting short hairpin RNA (shRNA) expressed from a DOX-inducible lentiviral vector Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Controllable inhibition of hepatitis B virus replication by a DR1-targeting short hairpin RNA (shRNA) expressed from a DOX-inducible lentiviral vector
Creator	Zhao, Fei Wang, Weiwei Li, J Hu, Kanghong Li, Jiafu Wang, W Zhao, X Peng, Hongquan Zhao, • Hu, K Hu, Á Peng, H Zhao, Á
Source	Medline; PMC
abstract	As a highly efficient delivery system, lentiviral vectors (LVs) have become a powerful tool to assess the antiviral efficacy of RNA drugs such as short hairpin RNA (shRNA) and decoys. Furthermore, recent advanced systems allow controlled expression of the effector RNA via coexpression of a tetracycline/doxycycline (DOX) responsive repressor (tTR-KRAB). Herein, this system was utilized to assess the antiviral effects of LV-encoded shRNAs targeting three conserved regions on the pregenomic RNA of hepatitis B virus (HBV), namely the region coding for the reverse transcriptase (RT) domain of the viral polymerase (LV-HBV-shRNA1), the core promoter (CP; LV-HBV-shRNA2), and the direct repeat 1 (DR1; LV-HBV-shRNA3). Transduction of just the LV-HBV-shRNA vectors into the stably HBV expressing HepG2.2.15 cell line showed significant reductions in secreted HBsAg and HBeAg, intracellular HBcAg as well as HBV RNA and DNA replicative intermediates for all vectors, however, most pronouncedly for the DR1-targeting shRNA3. The corresponding vector was therefore applied in the DOX-controlled system. Notably, strong interference with HBV replication was found in the presence of the inducer DOX whereas the antiviral effect was essentially ablated in its absence; hence, the silencing effect of the shRNA and consequently HBV replication could be strictly regulated by DOX. This newly established system may therefore provide a valuable platform to study the antiviral efficacy of RNA drugs against HBV in a regulated manner, and even be applicable in vivo. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11262-013-0886-2) contains supplementary material, which is available to authorized users.
has issue date	2013-02-09(xsd:dateTime)
bibo:doi	10.1007/s11262-013-0886-2
bibo:pmid	23397077
has license	no-cc
sha1sum (hex)	6036a70e7106d53efc5092bb6580fe46e3526eb4
schema:url	https://doi.org/10.1007/s11262-013-0886-2
resource representing a document's title	Controllable inhibition of hepatitis B virus replication by a DR1-targeting short hairpin RNA (shRNA) expressed from a DOX-inducible lentiviral vector
has PubMed Central identifier	PMC7089079
has PubMed identifier	23397077
schema:publication	Virus Genes
resource representing a document's body	covid:6036a70e7106d53efc5092bb6580fe46e3526eb4#body_text
is schema:about of	named entity 'LENTIVIRAL VECTOR' named entity 'responsive' named entity 'highly' named entity 'short hairpin RNA' named entity 'TARGETING' named entity 'DR1' named entity 'HEPATITIS B VIRUS' named entity 'POWERFUL' named entity 'CONSERVED' named entity 'EXPRESSION' named entity 'A TETRACYCLINE' named entity 'DELIVERY SYSTEM' named entity 'REGION' named entity 'RNA' named entity 'RECENT' covid:arg/6036a70e7106d53efc5092bb6580fe46e3526eb4 named entity 'REPRESSOR' named entity 'ALLOW' named entity 'SHORT HAIRPIN RNA' named entity 'ADVANCED' named entity 'HIGHLY' named entity 'CODING' named entity 'HEPATITIS B VIRUS' named entity 'EXPRESSED' named entity 'INDUCIBLE' named entity 'INHIBITION' named entity 'DOX' named entity 'SHORT HAIRPIN RNA' named entity 'VIRUS REPLICATION' named entity 'DIRECT REPEAT' named entity 'SYSTEMS' named entity 'ASSESS' named entity 'REVERSE TRANSCRIPTASE' named entity 'COEXPRESSION' named entity 'HAVE' named entity 'DRUGS' named entity 'EFFICIENT' named entity 'EFFECTOR' named entity 'VECTORS' named entity 'ENCODED' named entity 'HBV' named entity 'DOMAIN' named entity 'EFFECTS' named entity 'EFFICACY' named entity 'RESPONSIVE' named entity 'CONTROLLED' named entity 'REGIONS' named entity 'ANTIVIRAL' named entity 'CORE PROMOTER' named entity 'TARGETING' named entity 'VIRAL POLYMERASE' named entity 'TOOL' named entity 'SYSTEM' named entity 'DR1' named entity 'polymerase' named entity 'shRNA' named entity 'hepatitis B virus' named entity 'drugs' named entity 'domain' named entity 'antiviral' named entity 'shRNA' named entity 'targeting' named entity 'repressor' named entity 'DR1' named entity 'viral polymerase' named entity 'shRNA' named entity 'core promoter' named entity 'RNA' named entity 'antiviral'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software